Macrophage Activation Status Rather than Repolarization Is Associated with Enhanced Checkpoint Activity in Combination with PI3Kγ Inhibition | Citedby Results | Molecular Cancer Therapeutics | American Association for Cancer Research

Skip to Main Content

Skip Nav Destination

Macrophage Activation Status Rather than Repolarization Is Associated with Enhanced Checkpoint Activity in Combination with PI3Kγ Inhibition

Mol Cancer Ther (2021) 20 (6): 1080–1091.

This article has been cited by the following articles in journals that are participating in CrossRef Cited-by Linking.

Targeting the PI3K/AKT signaling pathway in anticancer research: a recent update on inhibitor design and clinical trials (2020–2023)

Dima A. Sabbah
Rima Hajjo
Sanaa K. Bardaweel
Haizhen A. Zhong

Expert Opinion on Therapeutic Patents (2024) 34 (3): 141.

mTORC1 activation in presumed classical monocytes: observed correlation with human size variation and neuropsychiatric disease

Karl Berner
Naci Oz
Alaattin Kaya
Animesh Acharjee
Jon Berner

Aging (2024) 16 (14): 11134.

Bacterial protoplast-derived nanovesicles carrying CRISPR-Cas9 tools re-educate tumor-associated macrophages for enhanced cancer immunotherapy

Mingming Zhao
Xiaohui Cheng
Pingwen Shao
Yao Dong
Yongjie Wu
Lin Xiao
Zhiying Cui
Xuedi Sun
Chuancheng Gao
Jiangning Chen
Zhen Huang
Junfeng Zhang

Nature Communications (2024) 15 (1)

Insights of immune cell heterogeneity, tumor-initiated subtype transformation, drug resistance, treatment and detecting technologies in glioma microenvironment

Tongzheng Chen
Wenbin Ma
Xin Wang
Qile Ye
Xintong Hou
Yiwei Wang
Chuanlu Jiang
Xiangqi Meng
Ying Sun
Jinquan Cai

Journal of Advanced Research (2024)

Targeting PI3K-gamma in myeloid driven tumour immune suppression: a systematic review and meta-analysis of the preclinical literature

Haonan Xu
Shannon Nicole Russell
Katherine Steiner
Eric O’Neill
Keaton Ian Jones

Cancer Immunology, Immunotherapy (2024) 73 (10)

Eganelisib combined with immune checkpoint inhibitor therapy and chemotherapy in frontline metastatic triple-negative breast cancer triggers macrophage reprogramming, immune activation and extracellular matrix reorganization in the tumor microenvironment

Brenda C O'Connell
Charley Hubbard
Nora Zizlsperger
Donna Fitzgerald
Jeffrey L Kutok
Judith Varner
Robert Ilaria
Melody A Cobleigh
Dejan Juric
Kate H R Tkaczuk
Anthony Elias
Arielle Lee
Shaker Dakhil
Erika Hamilton
Hatem Soliman
Stephane Peluso

Journal for ImmunoTherapy of Cancer (2024) 12 (8): e009160.

Research progress on the role of tumor‑associated macrophages in tumor development and their use as molecular targets (Review)

Chenglin Lu
Ying Liu
Linxuan Miao
Xiangle Kong
Huili Li
Haoran Chen
Xu Zhao
Bin Zhang
Xiaonan Cui

International Journal of Oncology (2023) 64 (2)

Therapeutic targeting of tumour myeloid cells

Simon T. Barry
Dmitry I. Gabrilovich
Owen J. Sansom
Andrew D. Campbell
Jennifer P. Morton

Nature Reviews Cancer (2023) 23 (4): 216.

Pan-PI3K inhibition with copanlisib overcomes Treg- and M2-TAM-mediated immune suppression and promotes anti-tumor immune responses

Simon Heller
Sarah Glaeske
Katja Gluske
Juliane Paul
Annika Böhme
Andreas Janzer
Helge Gottfried Roider
Anna Montebaur
Barbara Nicke
Ralf Lesche
Oliver von Ahsen
Oliver Politz
Ningshu Liu
Mátyás Gorjánácz

Clinical and Experimental Medicine (2023) 23 (8): 5445.

Structural Insights from Molecular Modeling of Isoindolin-1-One Derivatives as PI3Kγ Inhibitors against Gastric Carcinoma

Suparna Ghosh
Seung Joo Cho

Biomedicines (2022) 10 (4): 813.

Adenovirus-Mediated Inducible Expression of a PD-L1 Blocking Antibody in Combination with Macrophage Depletion Improves Survival in a Mouse Model of Peritoneal Carcinomatosis

Maria Buñuales
Maria Cristina Ballesteros-Briones
Manuela Gonzalez-Aparicio
Sandra Hervas-Stubbs
Eva Martisova
Uxua Mancheño
Ana Ricobaraza
Sara Lumbreras
Cristian Smerdou
Ruben Hernandez-Alcoceba

International Journal of Molecular Sciences (2021) 22 (8): 4176.